The Conversation (0)
iCo Therapeutics (TSXV:ICO) released its financial results for year ended December 31, 2012.
iCo Therapeutics (TSXV:ICO) released its financial results for year ended December 31, 2012.
As quoted in the press release:
2012 Financial & Operational Highlights
-
Appointment of Douglas G. Janzen to iCo’s Board of Directors.
-
Presented on the panel, Macular Edema Today and Tomorrow at the Retinal Physician Symposium conference.
-
Announced a $1.1Million non-repayable financial contribution from the National Research Council of Canada to support iCo’s Oral Amphotericin B (Amp B) delivery system as novel treatment for patients with Human Immunodeficiency Virus (HIV).
-
Highlighted iCo’s iDEAL study in the following JDRF publication: https://www.jdrf.org/files/General_Files/Get_Involved/TopResearch_Spring2012.pdf
-
Raised $2.55 million through an Overnight Marketed Offering. At the time of our offering we concluded the fundraising at 45 cents per unit and since the offering our share price has significantly appreciated.
-
Presented five posters on oral Amphotericin B delivery system at the AAPS Annual Meeting and Exposition, in Chicago, Illinois
Click here to read the full iCo Therapeutics (TSXV:ICO) press release.